V180 is inactivated, containing only the truncated form of the structural envelope protein, which prevents serotypes from interfering with each other. Because an inactivated virus has difficulty stimulating immunity on its own, V180 is being tested with various adjuvants to boost immunity.
The technology was originally developed at the National Institutes of Health.
V180 is indicated to prevent dengue fever
V180 is administered as an intramuscular injection
Clinical Trial NCT02450838: Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005) (Completed, No results posted)
- The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of adjuvanted (with Alhydrogel™) and nonadjuvanted formulations of V180 in healthy adults who have previously received the live-attenuated tetravalent dengue vaccine TV003 or TV005.
- Participants will be randomly assigned to receive one intramuscular injection of either adjuvanted V180, nonadjuvanted V180, or placebo at study entry (Day 1).
- Participants will record their temperature and any adverse events for 14 days after receiving the vaccination. Additional study visits will occur on Days 15, 28 and 180.
- Visits will include a physical examination and blood and urine collection.
- Study staff will contact participants by telephone at Days 7 and 90 (and at other occasional time points between Days 90 and 180) for health and safety follow-up monitoring.
Clinical Trial NCT01477580: Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001) (Completed, No results posted)
- This study will determine whether at least one formulation of an experimental dengue vaccine (V180) is safe and causes an immune response.